Cargando…

Public acceptability of COVID-19 vaccines and its predictors in Middle ‎Eastern/North African (MENA) countries: a systematic review‎

INTRODUCTION: COVID-19 vaccines emerged as a worldwide hope to contain the pandemic. However, many people ‎are still hesitant to receive these vaccines. We aimed to systematically review the public knowledge, perception, and acceptability of COVID-19 vaccines in the Middle East and North Africa (MEN...

Descripción completa

Detalles Bibliográficos
Autores principales: Dadras, Omid, SeyedAlinaghi, SeyedAhmad, Karimi, Amirali, Shamsabadi, Ahmadreza, Mahdiabadi, Sara, Mohammadi, Parsa, Amiri, Ava, Shojaei, Alireza, Pashaei, Zahra, Mirzapour, Pegah, Qaderi, Kowsar, MohsseniPour, Mehrzad, Alilou, Sanam, Mehraeen, Esmaeil, Jahanfar, Shayesteh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9196809/
https://www.ncbi.nlm.nih.gov/pubmed/35318872
http://dx.doi.org/10.1080/21645515.2022.2043719
Descripción
Sumario:INTRODUCTION: COVID-19 vaccines emerged as a worldwide hope to contain the pandemic. However, many people ‎are still hesitant to receive these vaccines. We aimed to systematically review the public knowledge, perception, and acceptability of COVID-19 vaccines in the Middle East and North Africa (MENA) countries and the predictors of vaccine acceptability in this region. METHODS: We systematically searched databases of PubMed, Scopus, Web of Science, and Cochrane and retrieved ‎all relevant studies by 5 August 2021. RESULTS: There was a considerable variation in the COVID-19 vaccine acceptance ‎rates, from 12% in a study from Israel to 83.3% in Kuwait, although two other studies from Israel mentioned 75% ‎and 82.2% acceptability rates. Concerns about the side effects and safety of the vaccine were the main reasons for ‎the lack of acceptability of taking the vaccine, which was reported in 19 studies. ‎ CONCLUSION: Several factors, such as age, gender, education level, and comorbidities, ‎are worthy of attention as they could expand vaccine coverage in the target population.‎